Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

GPCR

Structure Therapeutics Inc ADR

May 26 • 01:28PM ET

38.97

-0.22 -0.57 %

Healthcare • Biotechnology • USA • Mid • NASD

Peers: VKTX ALT MDGL RYTM CRNX

| Held by: IBB SBIO FDG FFSM EWX OZEM LRNZ ONEQ MID GXC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.69	Insider Own	2.33%	Shs Outstand	71.07M	Perf Week	7.91%
Market Cap	2.77B	Forward P/E	-	EPS next Y	-1.92	Insider Trans	0.00%	Shs Float	69.41M	Perf Month	-14.34%
Enterprise Value	1.32B	PEG	-	EPS next Q	-0.37	Inst Own	89.24%	Short Float	8.60%	Perf Quarter	-43.46%
Income	-170.73M	P/S	-	EPS this Y	-72.65%	Inst Trans	0.67%	Short Ratio	6.50	Perf Half Y	13.47%
Sales	0.00M	P/B	1.91	EPS next Y	-39.34%	ROA	-14.38%	Short Interest	5.97M	Perf YTD	-43.98%
Book/sh	20.36	P/C	1.90	EPS next 5Y	-25.76%	ROE	-15.03%	52W High	94.90 -58.94%	Perf Year	58.72%
Cash/sh	20.52	P/FCF	-	EPS past 3/5Y	-18.36% -40.35%	ROIC	-11.77%	52W Low	15.80 146.61%	Perf 3Y	21.77%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.65% 5.74%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-4.45%	Oper. Margin	-	ATR (14)	2.35	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	26.16	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	40.15	Recom	1.11
Dividend Gr. 3/5Y	- -	Current Ratio	26.16	EPS Q/Q	-28.61%	SMA20	-1.40%	Beta	-1.42	Target Price	108.31
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-15.32%	Rel Volume	0.19	Prev Close	39.19
Employees	220	LT Debt/Eq	0.00	Earnings	May 07 AMC	SMA200	-15.95%	Avg Volume	918.53K	Price	38.97
IPO	Feb 03, 2023	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.37% -	Trades		Volume	112,407	Change	-0.57%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-27-26	Initiated	Canaccord Genuity	Buy	$101
Mar-26-26	Initiated	Wolfe Research	Peer Perform
May-02-25	Initiated	Citigroup	Buy	$60
Feb-28-25	Initiated	William Blair	Outperform
Jan-08-25	Initiated	Stifel	Buy	$50
Dec-04-24	Initiated	H.C. Wainwright	Buy	$80
Sep-23-24	Initiated	Morgan Stanley	Overweight	$118
May-21-24	Initiated	JP Morgan	Overweight	$65
Apr-09-24	Initiated	Cantor Fitzgerald	Overweight	$65
Oct-19-23	Initiated	JMP Securities	Mkt Outperform	$90
Jul-27-23	Initiated	Piper Sandler	Overweight	$58
May-25-23	Resumed	Jefferies	Buy	$34 → $41
Feb-28-23	Initiated	SVB Securities	Outperform	$33
Feb-28-23	Initiated	Jefferies	Buy	$34
Feb-28-23	Initiated	Guggenheim	Buy	$50
Feb-28-23	Initiated	BMO Capital Markets	Outperform	$40

Show Previous Ratings

May-21-26 05:38AM	Lillys triple-acting obesity drug hits goal in Phase 3 trial (BioPharma Dive) +5.21%
May-07-26 04:05PM	Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights (GlobeNewswire)
Apr-27-26 04:05PM	Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions (GlobeNewswire)
Apr-14-26 04:05PM	Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel (GlobeNewswire)
Mar-17-26 03:20PM	This biotech is working on a GLP-1 pill that could be better than the Wegovy version (MarketWatch)
09:15AM	Loading…
09:15AM	Rival GLP-1 pill matches Wegovy weight loss data, adding to competitive pressure on Novo Nordisk (Proactive)
Mar-16-26 04:12PM	Structure Therapeutics Pops; But Can It Take On Lilly's Looming Obesity Pill? (Investor's Business Daily) +5.40%
10:46AM	Weight Loss Pill from Structure Therapeutics Trimmed the Most Pounds Yet. Is the Biotech a Takeover Candidate? (Barrons.com)
07:35AM	Structures GLP-1 pill shows best-in-class potential in obesity trial (BioPharma Dive)
07:00AM	Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron (GlobeNewswire)
Mar-05-26 08:12AM	Lilly Stock Down 5% in a Month: Should You Buy Now or Steer Clear? (Zacks) -5.43%
Feb-26-26 04:02PM	Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights (GlobeNewswire)
Feb-25-26 08:40AM	Lilly's GLP-1 Blockbusters Drive 2025 Revenue Surge: What's Ahead? (Zacks)
Feb-24-26 12:00PM	Lilly vs. Novo Nordisk: Obesity Drug Giants' Face-Off in 2026 (Zacks)
Feb-23-26 01:25PM	Novo Nordisk Dives As Next-Gen Obesity Drug Lags Eli Lilly's Kingpin (Investor's Business Daily)
06:58AM	Loading…
Feb-19-26 06:58AM	Structure Therapeutics (GPCR) Gained from Favorable Clinical Data (Insider Monkey)
Feb-18-26 07:22AM	Can LLY's Next-Gen Obesity Pipeline Sustain Growth Amid Competition? (Zacks)
Feb-12-26 08:42AM	How to Play Eli Lilly Stock Following a Robust Q4 Earnings Report (Zacks) -5.19%
Feb-10-26 10:49AM	Eli Lilly's 2025 Surge Sets the Stage for Another Big Year in 2026 (Zacks)
Feb-04-26 09:30AM	Healthcare ETFs to Watch as Novo Nordisk Tumbles on Poor Sales Outlook (Zacks)
Jan-23-26 09:18AM	Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It (Benzinga)
Jan-16-26 12:13PM	Jim Cramer on Structure Therapeutics: "I Don't Want to Touch It" (Insider Monkey)
10:47AM	LLY Stock Falls After FDA Reportedly Delays Obesity Drug Ruling (Zacks)
Jan-15-26 11:35AM	Structure Therapeutics Inc. (GPCR) Has Gained Over 130% in 3 Months. Here is Why (Insider Monkey)
11:07AM	Structure Therapeutics CEO Says Compounding Threat Looms For Future Obesity Treatments (Benzinga)
10:17AM	How Will Mounjaro and Zepbound Sales Aid LLY's Upcoming Q4 Results? (Zacks)
Jan-12-26 12:00PM	Funding for Risky Biotechs Is Returning (The Wall Street Journal)
Jan-11-26 04:05PM	Can This Stock Double Again in 2026? (Motley Fool)
Jan-09-26 11:19AM	Healthcare dealmakers head to San Francisco hoping for megamergers in 2026 (Reuters)
09:58AM	VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug (Zacks)
09:12AM	Loading…
Jan-08-26 09:12AM	H.C. Wainwright Upgrades Structure Therapeutics (GPCR) on Massive Arbitrage Opportunity for Oral GLP-1 (Insider Monkey)
Jan-05-26 10:37AM	LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock? (Zacks) -7.85%
Dec-24-25 10:49AM	NVO's First Oral Obesity Pill Approval: What Does it Mean for Lilly? (Zacks)
Dec-23-25 10:46AM	Novo Nordisk Wins FDA Nod for Oral Wegovy in Obesity, Stock Up (Zacks) +12.71%
Dec-22-25 10:11AM	What Awaits These 4 Biotech Stocks That More Than Doubled in 2025 (Zacks)
Dec-17-25 08:30AM	Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity (GlobeNewswire)
Dec-15-25 10:32AM	CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval (Zacks)
Dec-12-25 10:37AM	NVO Down 42% Year to Date: Is This an Indication to Sell the Stock? (Zacks)
Dec-11-25 04:28PM	Eli Lilly Puts Obesity Field 'On Notice' With Best-Ever Weight Loss (Investor's Business Daily)
04:01PM	Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs (GlobeNewswire)
10:23AM	Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge? (Zacks)
08:10AM	Eli Lilly's Experimental Obesity Drug Cut Weight By 23.7% (Investor's Business Daily)
Dec-10-25 10:17AM	Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies? (Zacks)
Dec-09-25 11:15PM	Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants (GlobeNewswire)
02:23PM	Structure Therapeutics (GPCR) Hits 52-Week High on Weight Loss Treatment Trial (Insider Monkey)
11:15AM	In The 'Uber Bull' Biotech Market, Is Structure The Next Metsera? (Investor's Business Daily)
09:27AM	GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron (Zacks)
Dec-08-25 08:15PM	Why Structure Therapeutics Stock Doubled and Then Some on Monday (Motley Fool) +102.49%
04:15PM	Structure Therapeutics Soars; CEO Says It Could Have 'Best In Class' Weight-Loss Drug (Investor's Business Daily)
04:01PM	Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants (GlobeNewswire)
12:46PM	Obesity Biotechs' Gains Hit Shares of Eli Lilly, Novo Nordisk (Barrons.com)
10:36AM	Structure Therapeutics Stock Jumps on Trial Results for Weight-Loss Pill (The Wall Street Journal)
09:12AM	Structure details positive trial data for a weight-loss pill, and the stock rockets (MarketWatch)
08:00AM	Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron (GlobeNewswire)
05:32AM	Dyne to seek Duchenne drug approval; Kymera, Wave and Structure shares soar (BioPharma Dive)
Dec-07-25 06:20PM	Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025 (GlobeNewswire)
Nov-16-25 10:14PM	BMO Capital Remains Bullish on Structure Therapeutics (GPCR), Cites Upcoming Trial Readouts (Insider Monkey)
Nov-06-25 04:01PM	Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights (GlobeNewswire)
Oct-30-25 02:11PM	Novo Nordisk Tries to Snatch a Weight-Loss Biotech From Pfizer. There Are Political Risks. (Barrons.com) +8.96%
Oct-24-25 11:39AM	NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now? (Zacks)
Sep-21-25 09:23AM	Structure Therapeutics Inc. (GPCR) Eyes Major 2025 Catalyst With Phase 2b Obesity Data (Insider Monkey)
Sep-12-25 08:15AM	This Under-the-Radar Healthcare Stock Could Soar in 2026 (Motley Fool)
Sep-02-25 08:30AM	Structure Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences (GlobeNewswire)
Aug-19-25 04:05PM	Viking Therapeutics Crashes 42% On Mixed Results For Its Weight-Loss Pill (Investor's Business Daily) -5.81%
Aug-11-25 08:22PM	Structure Therapeutics To Present Late-Breaking ADA Data on Oral Amylin Agonist ACCG-2671 (Insider Monkey) +7.36% +7.02%
Aug-07-25 04:20PM	Eli Lilly Dives 14% On A Shocking Obesity Setback, Sending Its Rivals Flying (Investor's Business Daily)
09:55AM	Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors (Benzinga)
09:01AM	Lilly Skids On A Shocking Obesity Setback. Novo, Viking, Structure Surge. (Investor's Business Daily)
Aug-06-25 04:01PM	Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights (GlobeNewswire)
Jun-24-25 05:42PM	Jefferies Reiterates a Buy Rating on Structure Therapeutics (GPCR) With a $79 PT (Insider Monkey)
Jun-20-25 07:30PM	Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671 (GlobeNewswire)
May-29-25 04:05PM	Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences (GlobeNewswire)
May-08-25 04:05PM	Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights (GlobeNewswire)
Apr-25-25 04:31PM	Is Structure Therapeutics Inc. (NASDAQ:GPCR) the Most Promising Small-Cap Stock According to Analysts? (Insider Monkey)
Apr-21-25 08:37AM	LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study (Zacks) +6.16%
Apr-18-25 11:25AM	Eli Lilly jumps as results from weight-loss pill study rival competitors (TipRanks)
10:26AM	JPMorgan says Lilly data highly favorable for Structure Therapeutics (TipRanks)
Apr-15-25 10:35AM	Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill (TipRanks)
10:00AM	NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback (Zacks)
Apr-14-25 11:12AM	Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today (Motley Fool) +19.18%
Mar-24-25 07:21PM	Structure Therapeutics CEO on latest GLP-1 developments (CNBC TV)
Mar-20-25 09:28AM	Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate (SeekingAlpha)
Mar-03-25 04:20PM	AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. (Investor's Business Daily) -5.94%
Feb-27-25 04:05PM	Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights (GlobeNewswire) +14.79%
Feb-14-25 07:56AM	Why Structure Therapeutics Stock Was Stumbling This Week (Motley Fool)
Jan-30-25 08:30AM	Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences (GlobeNewswire)
Dec-18-24 10:25AM	Merck Licenses a Weight-Loss Pill. Its Bad News for Obesity Biotechs. (Barrons.com) -11.37%
Dec-17-24 04:01PM	Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity (GlobeNewswire)
Dec-16-24 01:33PM	Is Structure Therapeutics Inc. (GPCR) the Best Weight Loss Stock to Buy Now According to Hedge Funds? (Insider Monkey)
Dec-08-24 06:05AM	Jefferies Predicts Up to ~1000% Surge for These 2 Strong Buy Stocks (TipRanks)
Nov-27-24 10:15AM	Why Is Structure Therapeutics Inc. (GPCR) Among the Best Up and Coming Stocks to Buy According to Analysts? (Insider Monkey)
Nov-22-24 07:45AM	Structure Therapeutics Inc. (GPCR): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts (Insider Monkey) +11.00%
Nov-15-24 08:30AM	Structure Therapeutics to Participate in the Jefferies London Healthcare Conference (GlobeNewswire) -9.34%
Nov-13-24 04:05PM	Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire)
04:01PM	Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity (GlobeNewswire)
Oct-31-24 08:30AM	Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek 2024 (GlobeNewswire) +8.69%
Oct-24-24 07:58PM	GPCR drugmaker Septerna amasses $288M in IPO (BioPharma Dive)
Oct-16-24 08:45AM	Structure Therapeutics (GPCR): Innovating Oral Therapies for Obesity and Diabetes (Insider Monkey) +7.41%
Oct-09-24 09:55AM	Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect? (Zacks)
Oct-04-24 08:00AM	As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer (Investor's Business Daily)

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

CEO & DirectorDr. Raymond C. Stevens Ph.D.

Co- FounderMr. Jun S. Yoon

Chief Technology OfficerDr. Yingli Ma Ph.D.

Chief Scientific Officer & GM of Structure ShanghaiDr. Xichen Lin Ph.D.

Ph.D.Dr. Blai Coll M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GPCR

Structure Therapeutics Inc ADR

Upgrade your Finviz experience